Search results for " Ly"

showing 10 items of 2487 documents

FTY720 reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia.

2011

Background The contribution of neuroinflammation and specifically brain lymphocyte invasion is increasingly recognised as a substantial pathophysiological mechanism after stroke. FTY720 is a potent treatment for primary neuroinflammatory diseases by inhibiting lymphocyte circulation and brain immigration. Previous studies using transient focal ischemia models showed a protective effect of FTY720 but did only partially characterize the involved pathways. We tested the neuroprotective properties of FTY720 in permanent and transient cortical ischemia and analyzed the underlying neuroimmunological mechanisms. Methodology/Principal Findings FTY720 treatment resulted in substantial reduction of c…

MaleDrugs and DevicesLymphocyteCerebrovascular DiseasesImmunologyNeuroimmunologyIschemialcsh:MedicineBrain EdemaNeuroprotectionProinflammatory cytokineBrain IschemiaBrain ischemiaMiceNeuropharmacologySphingosinemedicine.arteryhemic and lymphatic diseasesmedicineLeukocytesAnimalsLymphoid OrgansLymphocyteslcsh:ScienceStrokeBiologyNeuroinflammationMultidisciplinarybusiness.industryFingolimod HydrochlorideInterleukin-6Tumor Necrosis Factor-alphalcsh:RImmunologic Subspecialtiesmedicine.diseaseMice Inbred C57BLmedicine.anatomical_structureNeurologyPropylene GlycolsImmune SystemImmunologyMiddle cerebral arteryMedicineClinical Immunologylcsh:QbusinessImmunosuppressive AgentsResearch ArticlePLoS ONE
researchProduct

Emergence of tularemia in France: paradigm of the Burgundy region

2011

International audience; We report three consecutive cases of tularemia occurring in Burgundy, France, a region previously considered not endemic for tularemia. The patients presented with varied and unspecific clinical manifestations. The epidemiological circumstances, especially the mode of contamination, were not particularly suggestive of tularemia. Serological diagnosis was delayed in two cases because of the lack of significant antibody titers at the time of admission. In contrast, a diagnosis could readily be obtained in all three cases by detection of Francisella tularensis DNA from clinical samples using PCR-based methods. These cases highlight the increased incidence and geographic…

MaleEpidemiologyMESH: Lymph NodesCommunicable Diseases EmergingSerologyTularemia0302 clinical medicineMESH: Early DiagnosisEpidemiologyDiagnosisMESH: Communicable Diseases Emerging030212 general & internal medicineMESH: DoxycyclineFrancisella tularensisTularemia0303 health sciencesMESH: TularemiaMESH: Middle AgedbiologyMESH: Real-Time Polymerase Chain ReactionIncidence (epidemiology)[SDV.BID.EVO]Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE]Antibody titerGeneral Medicinerespiratory systemMiddle Aged3. Good healthAnti-Bacterial AgentsInfectious DiseasesFrancisella tularensis DNADoxycyclineFemaleFranceFluoroquinolonesAdultDNA BacterialMicrobiology (medical)medicine.medical_specialtyReal-Time Polymerase Chain Reactioncomplex mixtures03 medical and health sciencesMESH: Francisella tularensisMESH: Anti-Bacterial AgentsmedicineHumansFrancisella tularensisMESH: Humans030306 microbiologyMESH: AdultMESH: Fluoroquinolonesbiology.organism_classificationmedicine.diseasebacterial infections and mycosesVirologyMESH: DNA BacterialMESH: MaleMESH: FranceEarly DiagnosisbacteriaLymph NodesMESH: FemaleReal-time PCRInternational Journal of Infectious Diseases
researchProduct

Tumor necrosis factor (TNF) and lymphotoxin-a (LTA) polymorphisms and risk of non-hodgkin lymphoma in the interLymph consortium

2010

In an International Lymphoma Epidemiology Consortium pooled analysis, polymorphisms in 2 immune-system-related genes, tumor necrosis factor (TNF) and interleukin-10 (IL10), were associated with non-Hodgkin lymphoma (NHL) risk. Here, 8,847 participants were added to previous data (patients diagnosed from 1989 to 2005 in 14 case-control studies; 7,999 cases, 8,452 controls) for testing of polymorphisms in the TNF -308G>A (rs1800629), lymphotoxin-alpha (LTA) 252A>G (rs909253), IL10 -3575T>A (rs1800890, rs1800896), and nucleotide-binding oligomerization domain containing 2 (NOD2) 3020insC (rs2066847) genes. Odds ratios were estimated for non-Hispanic whites and several ethnic subgroups using 2-…

MaleEpidemiologyTNFGastroenterology0302 clinical medicineRisk Factorsimmune system diseaseshemic and lymphatic diseasesAged 80 and over0303 health scienceseducation.field_of_studyLymphoma Non-Hodgkinnon-Hodgkin lymphomaMiddle Aged3. Good healthInterleukin-10EuropeLTA030220 oncology & carcinogenesisFemaleLymphotoxin alphaAdultmedicine.medical_specialtyCanadaAdolescentTumor necrosis factorMeta- and Pooled AnalysesPopulationPolymorphism Single NucleotideWhite People03 medical and health sciencesYoung AdultInternal medicinemedicineHumansGenetic Predisposition to Diseaseeducation030304 developmental biologyAgedMycosis fungoidesbusiness.industryTumor Necrosis Factor-alphaAustraliaInternational AgenciesInterLymph ConsortiumOdds ratiomedicine.diseaseUnited StatesNon-Hodgkin's lymphomaLymphomaCase-Control StudiesImmunologyMantle cell lymphomalymphotoxin-alphabusinessDiffuse large B-cell lymphoma
researchProduct

Patterns of transmitted HIV drug resistance in Europe vary by risk group

2014

BACKGROUND: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. METHODS: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. RESULTS: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM…

MaleEpidemiologygenotypeHuman immunodeficiency virus 1HIV InfectionsRNA directed DNA polymerase inhibitorhigh risk patientLogistic regressionSettore MED/42 - Igiene Generale E ApplicataMen who have sex with men0302 clinical medicineImmunodeficiency Virusesmiddle agedstatistics and numerical data10. No inequalitySubstance Abuse Intravenous0303 health sciencesadulttransmissionvirus diseasesvirus transmissionhighly active antiretroviral therapyHIV immunopathogenesis3. Good healthMedical MicrobiologyViral Pathogenshigh risk behaviorMedicineScience & Technology - Other TopicsPOPULATIONShealth programanti human immunodeficiency virus agentUSERSmedicine.medical_specialtyScienceSexual BehaviorImmunologySexually Transmitted Diseasesintravenous drug abuse-Microbiology03 medical and health sciencesAntibiotic resistanceSDG 3 - Good Health and Well-beingHuman immunodeficiency virus infectionproteinase inhibitorHumansProtease InhibitorshumanHeterosexualityMicrobial PathogensseroconversionMedicine and health sciencesScience & TechnologyGenitourinary InfectionsMUTATIONSVirologymajor clinical studyLogistic Modelstransmitted drug resistance mutationHeterosexualityHIV-1Viral Diseases:Medical sciences: 700::Basic medical dental and veterinary sciences: 710::Medical immunology: 716 [VDP]drug responsemen who have sex with menDrug resistanceClinical immunologygeographyAPPEARANCEmale homosexualityMedizinische Fakultätimmune system diseasesEpidemiologyINFECTIONMedicine and Health Sciencessubstance abuse030212 general & internal medicineriskMultidisciplinaryACTIVE ANTIRETROVIRAL THERAPYTransmission (medicine)virus mutationQRarticleObstetrics and GynecologyHIV diagnosis and managementMiddle AgedvirologyMultidisciplinary SciencesEuropeInfectious Diseasesfemale:Medisinske fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710::Medisinsk immunologi: 716 [VDP]Reverse Transcriptase InhibitorsHIV clinical manifestationsFemaleepidemiologyblood samplingHIV drug resistanceResearch ArticleAdultRiskrisk-groupAnti-HIV AgentsUrologyprevalenceInfectious Disease Epidemiologysexual behaviorRisk-Takingmaleantiviral resistanceInternal medicineDrug Resistance Viralmedicinecontrolled studyddc:610Homosexuality Male030304 developmental biologydrug resistanceBiology and life sciencesbusiness.industrystatistical modelHIVCD4 lymphocyte countheterosexualitynonnucleoside reverse transcriptase inhibitorHuman immunodeficiency virus 1 infectionDiagnostic medicineINDIVIDUALSdrug effectsWomen's Healthbusinesstrend study
researchProduct

A Novel Risk Locus at 6p21.3 for Epstein-Barr Virus-Positive Hodgkin Lymphoma

2015

Abstract Background: A proportion of the genetic variants involved in susceptibility to Hodgkin lymphoma differ by the tumor's Epstein–Barr virus (EBV) status, particularly within the MHC region. Methods: We have conducted an SNP imputation study of the MHC region, considering tumor EBV status in 1,200 classical Hodgkin lymphoma (cHL) cases and 5,726 control subjects of European origin. Notable findings were genotyped in an independent study population of 468 cHL cases and 551 controls. Results: We identified and subsequently replicated a novel association between a common genetic variant rs6457715 and cHL. Although strongly associated with EBV-positive cHL [OR, 2.33; 95% confidence interva…

MaleEpstein-Barr Virus InfectionsEpidemiologyGenome-wide association studySUSCEPTIBILITYDISEASEMajor Histocompatibility Complex0302 clinical medicineNodular sclerosishemic and lymphatic diseasespolycyclic compoundsNetherlandsAged 80 and over0303 health scienceseducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyfood and beveragesMiddle AgedHodgkin Disease3. Good healthOncology030220 oncology & carcinogenesisUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Chromosomes Human Pair 6FemaleINFECTIOUS-MONONUCLEOSISSUBTYPEAdultAdolescentPopulationLocus (genetics)macromolecular substancesBiologyScandinavian and Nordic CountriesPolymorphism Single NucleotideSEQUENCE03 medical and health sciencesYoung AdultEBVmedicineSNPHumansGenetic Predisposition to DiseaseGENOME-WIDE ASSOCIATIONeducationEpstein–Barr virus infection030304 developmental biologyAgedCase-control studyEpstein-Barr Virus Positivemedicine.diseaseCase-Control StudiesImmunology[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyCancer Epidemiology Biomarkers & Prevention
researchProduct

Burkitt lymphoma with a granulomatous reaction: an M1/Th1‐polarised microenvironment is associated with controlled growth and spontaneous regression

2021

Aims Burkitt lymphoma (BL) is an aggressive B-cell lymphoma that, in some instances, may show a granulomatous reaction associated with a favourable prognosis and occasional spontaneous regression. In the present study, we aimed to define the tumour microenvironment (TME) in four such cases, two of which regressed spontaneously. Methods and results All cases showed aggregates of tumour cells with the typical morphology, molecular cytogenetics and immunophenotype of BL surrounded by a florid epithelioid granulomatous reaction. All four cases were Epstein-Barr virus (EBV)-positive with type I latency. Investigation of the TME showed similar features in all four cases. The analysis revealed a p…

MaleEpstein-Barr Virus InfectionsHerpesvirus 4 HumanHistologyAdolescentM1 polarised macrophagesTh1 T cellsExpressionBiologyT-Cell ResponsesVirusPathology and Forensic MedicineProinflammatory cytokineMolecular cytogeneticsOriginImmunophenotypingEBVM1 polarised macrophagehemic and lymphatic diseasesTumor MicroenvironmentmedicineHumansM1 polarized macrophagesAgedInhibitionMacrophagesBurkitt lymphomaBurkitt lymphoma; EBV; In Situ lymphoid neoplasia; M1 polarized macrophages; Microenvironment; Th1 T cells; granulomatous reactionB-CellsGeneral MedicineMiddle AgedTh1 Cellsmedicine.diseaseBurkitt LymphomamicroenvironmentRegressionLymphomain-situ lymphoid neoplasiagranulomatous reactionCancer researchFemaleTherapyCellular immunotherapyInfectionEarly phaseBurkitt lymphoma EBV granulomatous reaction in-situ lymphoid neoplasia M1 polarised macrophages microenvironment Th1 T cellsIn Situ lymphoid neoplasiaEpstein-Barr-VirusHistopathology
researchProduct

Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes.

2012

Abstract Normal human erythroid cell maturation requests the transcription factor GATA-1 and a transient activation of caspase-3, with GATA-1 being protected from caspase-3–mediated cleavage by interaction with the chaperone heat shock protein 70 (Hsp70) in the nucleus. Erythroid cell dysplasia observed in early myelodysplastic syndromes (MDS) involves impairment of differentiation and excess of apoptosis with a burst of caspase activation. Analysis of gene expression in MDS erythroblasts obtained by ex vivo cultures demonstrates the down-regulation of a set of GATA-1 transcriptional target genes, including GYPA that encodes glycophorin A (GPA), and the up-regulation of members of the HSP70…

MaleErythroblasts[SDV]Life Sciences [q-bio]Biochemistry0302 clinical medicineTranscription (biology)hemic and lymphatic diseasesGene expressionErythropoiesisGATA1 Transcription FactorCells CulturedCaspaseComputingMilieux_MISCELLANEOUSOligonucleotide Array Sequence AnalysisAged 80 and over0303 health sciencesbiologyCaspase 3Reverse Transcriptase Polymerase Chain ReactionCell DifferentiationU937 CellsHematologyMiddle Agedmedicine.anatomical_structure030220 oncology & carcinogenesisFemaleAdultGreen Fluorescent ProteinsImmunoblottingImmunology03 medical and health sciencesErythroid CellsmedicineHumansHSP70 Heat-Shock ProteinsTranscription factorAged030304 developmental biologyCell NucleusGene Expression ProfilingCell BiologyMolecular biologyCell nucleusMicroscopy FluorescenceApoptosisMyelodysplastic SyndromesChaperone (protein)Mutationbiology.proteinNuclear localization sequence
researchProduct

Presence of calreticulin mutations in JAK2-negative polycythemia vera

2014

Abstract Calreticulin (CALR) mutations have recently been reported in JAK2- and MPL-negative Myeloproliferative Neoplasms (MPN), particularly essential thrombocythemia (ET) and primary myelofibrosis (PMF).The clinical course of sporadic CALR-mutated patients seems to be more indolent than that of JAK2-mutated patients. In contrast, no CALR mutation has been found in the 647 published cases of Polycythemia Vera (PV) patients tested. Consequently, CALR mutations were considered exclusive to JAK2 and MPL mutations. Since 98% of PV patients harbor a JAK2 mutation (mostly the V617F mutation in exon 14 and more rarely, in exon 12), the absence of CALR mutations in PV seemed logical. Here, we desc…

MaleErythrocytesMESH: Thrombocytosismedicine.disease_causeMESH: Polycythemia VeraBiochemistryMESH: Janus Kinase 2MESH: GenotypeHemoglobinsMESH: Aged 80 and overPolycythemia verahemic and lymphatic diseasesPolycythemia VeraMESH: HeterozygoteAged 80 and overThrombocytosisMESH: AgedMutation[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyJanus kinase 2biologyMESH: ErythrocytesExonsHematologyLeukemiaMESH: HemoglobinsMESH: Primary MyelofibrosisThrombocythemia EssentialHeterozygoteMESH: MutationGenotypeMESH: CalreticulinImmunologyContext (language use)medicineHumansMyelofibrosisAllelesAgedMESH: HumansEssential thrombocythemiabusiness.industryMESH: AllelesCell BiologyJanus Kinase 2medicine.diseaseMESH: MalePrimary MyelofibrosisMESH: Gene DeletionMutationImmunologybiology.proteinCancer researchMESH: Thrombocythemia EssentialCalreticulinMESH: ExonsbusinessCalreticulinGene Deletion[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBlood
researchProduct

Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits.

2018

Abstract Marketed formulations of erythropoietin (EPO) ior®EPOCIM, MIRCERA® and two newly developed pegylated-EPO analogues (PEG-EPO 32 and 40 kDa) formulations were intravenously administered to New Zealand rabbits. A semi-mechanistic Pharmacokinetic/Pharmacodynamic (PK/PD) model describing in a simultaneous and integrated form the time course of reticulocytes, red blood cells and hemoglobin was built to account for the time course of hematopoiesis stimulation after erythropoietin administration. Data analysis was performed based on the population approach with the software NONMEM version 7.3. Erythropoietin disposition of each of the administered formulations was best described with a two…

MaleErythrocytesReticulocytesDrug CompoundingPopulationPharmaceutical ScienceBiological AvailabilityPharmacology030226 pharmacology & pharmacyModels BiologicalPolyethylene Glycols03 medical and health sciencesHemoglobins0302 clinical medicinePharmacokineticshemic and lymphatic diseasesMedicineAnimalseducationErythropoietinVolume of distributioneducation.field_of_studybusiness.industryRecombinant ProteinsNONMEMHematopoiesisHaematopoiesisErythropoietin030220 oncology & carcinogenesisPharmacodynamicsInjections IntravenousHematinicsLinear ModelsHemoglobinRabbitsbusinessmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by (18)FDG-PET/CT

2017

Abstract Objectives The objective of this study was to investigate fludeoxyglucose F 18 positron emission tomography/computed tomography ( 18 FDG-PET/CT) parameters as predictive of response after stereotactic ablative radiotherapy (SABR) for lung oligometastases. Methods The inclusion criteria of the current retrospective study were as follows: (1) lung oligometastases treated by SABR, (2) presence of 18 FDG-PET/CT before and after SABR for at least two subsequent evaluations, (3) Karnofsky performance status higher than 80, and (4) life expectancy longer than 6 months. All patients were treated with a biologically equivalent dose of at least 100 Gy with an alpha/beta ratio of 10. The foll…

MaleFludeoxyglucose F-18Lung Neoplasmsmedicine.medical_treatment18FDG-PET/CT; Lung malignancies; Predictive factors; SABR; Adenocarcinoma; Aged; Aged 80 and over; Carcinoma Non-Small-Cell Lung; Carcinoma Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden; Radiosurgery; Oncology; Pulmonary and Respiratory MedicineSABR volatility model030218 nuclear medicine & medical imaging0302 clinical medicinePositron Emission Tomography Computed TomographyAblative case80 and overMedicineNon-Small-Cell LungSABRmedicine.diagnostic_test(18)FDG-PET/CTMiddle AgedPrognosisTumor Burdenmedicine.anatomical_structureLocalOncologyPositron emission tomography030220 oncology & carcinogenesisLymphatic MetastasisFemaleRadiologyPredictive factorsPulmonary and Respiratory Medicinemedicine.medical_specialtyLung malignanciesStandardized uptake value18FDG-PET/CTAdenocarcinomaRadiosurgery03 medical and health sciencesFluorodeoxyglucose F18HumansAgedNeoplasm StagingRetrospective StudiesLungbusiness.industryCarcinomaRetrospective cohort studyRadiation therapyNeoplasm RecurrenceSquamous CellRadiopharmaceuticalsbusinessNuclear medicineFollow-Up Studies(18)FDG-PET/CT; Lung malignancies; Predictive factors; SABR
researchProduct